Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer

Sang Mi Kim; Eun Heui Kim; Bo Hyun Kim; Jong Ho Kim; Su Bin Park; Yoon Jeong Nam; Kang Hee Ahn; Min Young Oh; Won Jin Kim; Yun Kyung Jeon; Sang Soo Kim; Yong Ki Kim; In Ju Kim

doi:10.3803/EnM.2015.30.4.494

Articles

Page Path: HOME > Endocrinol Metab > Volume 30(4); 2015 > Article

Original Article Clinical Study Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer: Sang Mi Kim^1*, Eun Heui Kim^2*, Bo Hyun Kim^2,3, Jong Ho Kim², Su Bin Park², Yoon Jeong Nam², Kang Hee Ahn², Min Young Oh¹, Won Jin Kim², Yun Kyung Jeon², Sang Soo Kim², Yong Ki Kim⁴, In Ju Kim²; Endocrinology and Metabolism 2015;30(4):494-501.
DOI: https://doi.org/10.3803/EnM.2015.30.4.494
Published online: December 31, 2015

3,698 Views
36 Download
31 Crossref
33 Scopus

¹Department of Internal Medicine, Dongeui Medical Center, Busan, Korea.

²Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.

³Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

⁴Kim Yong Ki Internal Medicine Clinic, Busan, Korea.

Corresponding author: Bo Hyun Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea. Tel: +82-51-240-7678, Fax: +82-51-254-3237, pons71@hanmail.net

*These authors contributed equally to this work.

• Received: February 24, 2015 • Revised: March 18, 2015 • Accepted: June 23, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
Article information
References

ABSTRACT

Background
Several inflammatory biomarkers, especially a high preoperative neutrophil-to-lymphocyte count ratio (NLR) and platelet-to-lymphocyte count ratio (PLR), are known to be indicator of poor prognosis in several cancers. However, very few studies have evaluated the significance of the NLR and PLR in papillary thyroid cancer (PTC). We evaluated the association of the preoperative NLR and PLR with clinicopathological characteristics in patients with PTC.
Methods
This study included 1,066 female patients who underwent total thyroidectomy for PTC. Patients were stratified into 4 quartiles by preoperative NLR and PLR. And the combination of preoperative NLR and PLR was calculated on the basis of data obtained value of tertile as follows: patients with both an elevated PLR and an elevated NLR were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.
Results
The preoperative NLR and PLR were significantly lower in patients aged ≥45 years and in patients with Hashimoto's thyroiditis. The PLR was significantly higher in patients with tumor size >1 cm (P=0.021).When the patients were categorized into the aforementioned four groups, the group with the higher preoperative PLR was found to have a significantly increased incidence of lateral lymph node metastasis (LNM) (P=0.018). However, there are no significant association between the combination of preoperative NLR and PLR and prognostic factors in PTC patients.
Conclusion
These results suggest that a preoperative high PLR were significant associated with lateral LNM in female patients with PTC.
Keywords: Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Thyroid neoplasms; Prognosis

INTRODUCTION

In cancer patients, variations in clinical outcomes are associated with the oncological characteristics of the tumor and host responses to systemic inflammation. In particular, systemic inflammatory responses in malignancies may arise from nonspecific events that are altered by neuroendocrine metabolism, these may include hematopoietic changes, endocrine hormones, and changes secondary to tumor hypoxia, necrosis, or local tissue damage [1].

The tumor microenvironment and the inflammatory response in particular play several important roles in a variety of cancer, by promoting tumor cell proliferation, survival, angiogenesis, invasion, and metastasis. This is achieved through the release of T lymphocytes, chemokines, activated cytokines, interleukin-6 (IL-6), tumor necrosis factor α, and C-reactive protein (CRP), leading to neutrophilia. Such dysregulation of the immune system and the response to hormones may alter the effect of chemotherapy [2 3 4].

Recent studies have shown that several biomarkers associated with the inflammatory response, especially CRP, the neutrophil-to-lymphocyte count ratio (NLR), and the platelet-to-lymphocyte count ratio (PLR), are predictors of a poor prognosis [3]. A high preoperative NLR is a poor prognostic marker in some cancers, including cholangiocarcinoma as well as lung, gastric, pancreatic, colorectal, and ovarian cancers [5 6 7 8 9 10 11], and a high preoperative PLR is associated with a poor prognosis in pancreatic and operable colorectal cancers [11 12]. However, only a few studies have evaluated the significance of the NLR in thyroid cancer [13 14], and, to the best of our knowledge, there has been no studies investigating the PLR in patients with papillary thyroid cancer (PTC).

In this study, we evaluated the association between the preoperative NLR and PLR and the clinicopathological characteristics of patients with PTC.

We performed a retrospective chart review of 1,194 patients who underwent total thyroidectomy for PTC at Pusan National University Hospital between February 1, 2011 and May 31, 2013 to collect their clinical characteristics and demographic data.; Laboratory data were obtained from screening blood samples collected up to 2 weeks prior to total thyroidectomy, while thyroid-stimulating hormone (TSH) levels were measured before surgery. Complete blood counts, and automated differential counts were obtained 1 day before surgery. The NLR was calculated by dividing neutrophil count by the lymphocyte count; similarly, the PLR was calculated by dividing the platelet count by the lymphocyte count. Fasting morning blood samples were collected for these analyses.; Some earlier studies revealed that women in an immunocompromised state have higher neutrophil counts than men, probably because of sex hormones [15 16]. Accordingly, we surmised that there would be a gender-based difference in neutrophil counts in some pathologic conditions such as thyroid cancer. Additionally, it has been reported that gender influences clinicopathological features that predict the prognosis of PTC [17]. Therefore, we excluded male patients from the study (n=128), and investigated the association between the preoperative NLR and PLR and the clinicopathological features of 1,066 female patients with PTC. These female patients were reassigned into quartiles based on the preoperative NLR and PLR.; A previous study showed that the combined evaluation of the NLR and PLR was superior to the evaluation of the NLR or PLR alone as a predictive factor in patients with esophageal cancer [18]. Thus, we assumed that the combination of NLR and PLR was more likely to predict poor clinicopathological factors than the NLR or PLR alone in patients with PTC.; The patients were stratified into tertile groups based on the preoperative NLR and PLR. Then the combination of NLR and PLR was calculated on the basis of data obtained value of 3rd tertile as follows: patients with both an elevated PLR (>144.07) and an elevated NLR (>1.88) were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.; Central compartment neck dissections were routinely performed during total thyroidectomy; selective neck dissections were performed when node metastasis was suspected by ultrasonography or computed tomography findings, or upon positive cytological findings in samples obtained by preoperative fine needle aspiration from suspicious cervical neck lymph nodes.; Body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared. Tumor size was determined according to the greatest diameter of the lesion, based on postoperative biopsy results. Patients were staged according to the TNM classification system of the American Joint Committee on Cancer [19]. The T stage was classified as 1/2 or 3/4, while the N stage was classified according to lymph node metastasis (LNM) (N0 vs. N1) and lateral LNM (N0+N1a vs. N1b).; We tested for Hashimoto's thyroiditis, which was identified by diffuse lymphocyte infiltration, and lymphoid follicular formation in postoperative biopsy samples. We used the Seeplex BRAF ACE detection kit (Seegene, Seoul, Korea) to detect the BRAF V600E mutation in tumor tissues after thyroidectomy.; Informed consent was obtained from all patients, prior to thyroidectomy. The study was approved by the Institutional Review Board at Pusan National University Hospital, Busan, Korea.
Statistical analysis: Statistical analyses were performed using SPSS version 21.0 (IBM Co., Armonk, NY, USA). The Student t test was used to evaluate the relationship between the preoperative NLR and PLR and the other clinicopathological characteristics of PTC. One-way analysis of variance and Pearson chi-square test were used to compare different quartiles. Among the continuous variables, NLR, PLR, TSH, and tumor size are expressed as the median and interquartile range (IQR) age, BMI, and the number of tumors are expressed as mean±standard deviation. A P<0.05 was considered statistically significant.

RESULTS

A total of 1,066 female PTC patients were included in this analysis. Table 1 shows the relationships between the preoperative NLR and PLR values, and the clinicopathological characteristics of PTC. The preoperative NLR and PLR were significantly lower in patients aged ≥45 years and in patients with Hashimoto's thyroiditis. The PLR was significantly higher in patients with tumor size >1 cm; the median PLR was 139.89, with an IQR of 129.17 (vs. 132.41 with an IQR of 124.41 in patients with tumor size ≤1 cm; P=0.021). The preoperative NLR and PLR were not associated with multifocality, extrathyroidal extension (ETE), lateral LNM, lymphovascular invasion (LVI), the BRAF V600E mutation, tumor size, T stage, or LNM.

Patients were stratified by quartiles according to the preoperative NLR and PLR, and the prevalence of prognostic factors was compared between preoperative NLR and PLR quartiles (Tables 2, 3). Table 2 shows the relationships between clinicopathologic factors and NLR quartiles. The older patients had significant lower LNR values, but the differences were only between quartile 1 and quartile 3 and 4 in post hoc analysis. Significant differences were found between the NLR and LVI (P=0.006), but, there was not a meaningful correlation between NLR and LVI.

Table 3 showed that increasing preoperative PLR values from quartile 1 to quartile 3 were associated with increasing incidences of lateral LNM (P=0.018), with a positive correlation between the preoperative PLR from quartile 1 to quartile 3 (r=0.032, P=0.003, data not shown) and lateral LNM. However, patients in quartile 4 had a lower incidence of lateral LNM than patients in quartile 2 and 3. The older patients had significant lower PLR values, but the differences were significant only between quartile 1 and quartile 2, 3, and 4 in post hoc analysis. The preoperative PLR were not significantly associated with other clinicopathological factors (e.g., BMI, tumor size, TSH, T stage, LNM, multifocality, ETE, LVI, and the BRAF V600E mutation).

The higher value of combination of preoperative NLR and PLR were significantly associated with younger age in one way analysis of variance (P=0.004), but the differences were significant only between the score 0 and the score 2 (Table 4). There are no correlation between the combination of preoperative NLR and PLR and other prognostic factors (e.g., BMI, tumor size, TSH, T stage, LNM, lateral LNM, multifocality, ETE, LVI, and the BRAF V600E mutation).

DISCUSSION

Systemic inflammation has been reported to contribute to cancer development and progression, through the promotion of proliferation, survival, migration, and angiogenesis, as well as the suppression of antitumor immunity through the release of chemokines, especially regulatory T cells [20 21].

The mechanism underlying the association of a high NLR with a poor cancer prognosis remains unknown. Cancers have been shown to secrete myeloid growth factors, such as granulocyte colony-stimulating factor, IL-1, IL-6, and tumor necrosis factor-alpha, which may result in tumor-related leukocytosis and neutrophilia [12]. Accordingly, neutrophils promote cancer progression and stimulate the tumor microenvironment by releasing tumor growth promoting factors, such as vascular endothelial growth factor [22 23], hepatocyte growth factor [24], IL-6 [25], IL-8 [26], matrix metalloproteinases [27], and elastases [28].

The exact mechanisms underlying the association between an elevated PLR values and the biological behavior of cancer cells remain unclear. One hypothesis is that megakaryocyte-mediated thrombocytosis may result from the release of proinflammatory mediators such as IL-1, IL-2, and IL-6 [29]. Moreover, a high PLR value may be considered an indicator of inflammation [20].

Several studies have reported that a high NLR may be associated with a poor prognosis of solid tumor cancers, including lung, gastric, pancreatic, ovarian, and colorectal cancers, in addition to colorectal liver metastases, and cholangiocarcinomas [5 6 7 8 9 10 30 31]. Moreover, the PLR has recently been identified as an independent prognostic factor in patients undergoing potentially curative resections for pancreatic and operable colorectal cancers [3 11]; the PLR is also associated with a poor prognosis in breast cancer patients [32]. The combination of preoperative NLR and PLR has been shown to be significantly associated with the risk of cervical stromal involvement in patients with endometrial cancer [33]. Thus, the preoperative NLR and/or PLR are independent prognostic factors for several malignancies.

Previous studies have demonstrated that neutrophil viability and counts were significantly higher in women than in men because of the effect of sex hormones [14]. Furthermore, another study showed that female patients had higher circulating neutrophil counts, lower lymphocyte counts, and consequently higher NLR, indicating a more immunocompromised state than in male patients during the days immediately following surgery for stomach cancer [15]. Based on these results, we hypothesized that female patients have a higher white blood cell count than male patients under similar circumstances, which is why male patients were excluded in this study.

Liu et al. [34] previously showed that a high preoperative NLR was associated with increased tumor size and a high risk of recurrence in differentiated thyroid cancers. In this study, the NLR did not have significant association with the clinicopathological clinicopathological characteristics in PTC patients. But an elevated PLR values (especially in the first to third quartiles) were associated with an increased risk of lateral LNM (Table 3). However, patients in the fourth quartiles (PLR >156.25) had a lower incidence of lateral LNM than those belonging to the second and third quartiles. Seretis et al. [13] have reported similar results, showing a significant association of between a high NLR and thyroid cancer, especially for NLR >2.5, although the third (NLR >2.5 to 3.0) and fourth (NLR >3 to 6.9) quartiles showed lower incidences of thyroid cancer than the first and second. Although further large multicenter studies are required to confirm this association in thyroid cancer patients, our results suggest that there is a weak association between the NLR or PLR and prognosis in thyroid cancer once the NLR or PLR exceeds a certain value. Previous study showed that combination of NLR and PLR value was found to be much more applicable for predicting postoperative survival than patient stratification according to either the NLR or PLR alone in an esophageal squamous cell carcinoma [18]. Therefore we evaluated the usefulness of combination of NLR and PLR for predicting prognostic factor in patients with PTC. Unfortunately, our result showed no significant correlation with prognostic factors in PTC patients.

There were several limitations to our study. First, our study design was retrospective and only Asian patients in single institution were included; hence, our study did not represent the general population. Second, some studies have reported that chemotherapy can normalize an elevated NLR, and that patients with a normalized NLR may have improved outcomes [35 36]. However, our study did not evaluate the changes in NLR and PLR after thyroidectomy, or radioactive iodine therapy. Third, serum CRP levels are not evaluated during routine preoperative laboratory examinations of thyroid cancer patients. Neutrophil and lymphocyte counts may be influenced by infections, inflammation, medication, and other noncancerous conditions [37 38]. As we did not evaluate other medical conditions or medications, our results might be influenced by these confounding factors. Fourth, this study included only female patients with PTC.

Despite these limitations, this study offers some insight on our understanding of the link between preoperative inflammatory marker such as NLR, PLR and clinicopathological characteristics in patients with PTC. To the best of our knowledge, this study was the first study for association between PLR and prognostic factors in patients with PTC.

In conclusion, higher preoperative PLR were associated with lateral LNM in patients with PTC. Measurement of the PLR is cost-effective, safe, and readily available. Thus, preoperative PLR may be valuable for predicting adverse clinicopathological outcomes in PTC. More large-scale prospective studies are required to validate our results, before the preoperative NLR or PLR can be used as biomarkers for risk stratification.

Acknowledgements

ACKNOWLEDGMENTS

This work was supported by clinical research grant from Pusan National University Hospital 2015.

Article information

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223–226. Article PubMed
2. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 2012;33:749–756. Article PubMed PDF
3. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149–163. Article PubMed
4. Kim S, Cho SW, Min HS, Kim KM, Yeom GJ, Kim EY, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab (Seoul) 2013;28:192–198. Article PubMed PMC
5. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215–220. Article PubMed
6. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181–184. Article PubMed
7. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007;246:806–814. Article PubMed
8. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008;34:55–60. Article PubMed
9. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008;97:513–518. Article PubMed
10. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15–23. Article PubMed PDF
11. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466–472. Article PubMed
12. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–222. Article PubMed
13. Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013;205:691–696. Article PubMed
14. Han SW, Kang SY, Kim SK, Youn HJ, Jung SH. Clinical significance of blood neutrophil-to-lymphocyte ratio in patients with papillary thyroid carcinoma. Korean J Endocr Surg 2014;14:184–189.Article
15. Gwak MS, Choi SJ, Kim JA, Ko JS, Kim TH, Lee SM, et al. Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med Sci 2007;22(Suppl):S104–S108. Article PubMed PMC
16. Molloy EJ, O'Neill AJ, Grantham JJ, Sheridan-Pereira M, Fitzpatrick JM, Webb DW, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003;102:2653–2659. Article PubMed PDF
17. Ito Y, Miyauchi A, Kihara M, Kobayashi K, Miya A. Prognostic values of clinical lymph node metastasis and macroscopic extrathyroid extension in papillary thyroid carcinoma. Endocr J 2014;61:745–750. Article PubMed
18. Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther 2013;6:1605–1612. PubMed PMC
19. Edge SB. American Joint Committee on Cancer. American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual; 7th ed. New York: Springer; 2010.
20. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010;200:197–203. Article PubMed
21. Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 2013;11:337–341. Article PubMed
22. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999;134:1325–1331. Article PubMed
23. Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy 2003;83:182–203. Article PubMed
24. McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol 2001;27:396–403. Article PubMed
25. Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłonski J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 2001;49:63–69. PubMed
26. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003;103:335–343. Article PubMed
27. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001;189:197–206. Article PubMed
28. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002;168:5798–5804. Article PubMed
29. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913–922. Article PubMed
30. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008;7:331–337. Article PubMed
31. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008;44:251–256. Article PubMed
32. Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 2014;110:2524–2530. Article PubMed PMC PDF
33. Wang D, Yang JX, Cao DY, Wan XR, Feng FZ, Huang HF, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther 2013;6:211–216. PubMed PMC
34. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013;107:493–497. Article PubMed
35. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805–5813. Article PubMed
36. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288–1295. Article PubMed PMC PDF
37. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 2011;11:445–452. Article PubMed
38. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111:636–642. Article PubMed

Table 1

The Association between Preoperative NLR and PLR Values and the Clinicopathological Characteristics of Papillary Thyroid Cancer

Characteristic	Patients, n (%)	NLR		PLR
Characteristic	Patients, n (%)	Median (IQR)	P value	Median (IQR)	P value
Age, yr			0.001		<0.001
<45	324 (30.4)	1.75 (1.03-2.31)		135.60 (91.00-163.06)
≥45	742 (69.6)	1.52 (1.16-2.00)		123.60 (99.32-151.42)
Tumor size, cm			0.522		0.021
≤1	774 (75.6)	1.59 (1.20-2.06)		124.41 (103.13-155.09)
>1	292 (27.4)	1.53 (1.22-2.12)		129.17 (106.24-162.44)
T stage			0.370		0.801
1/2	944 (88.6)	1.57 (1.21-2.08)		125.62 (104.05-156.11)
3/4	122 (11.4)	1.63 (1.20-2.13)		127.70 (97.84-156.75)
LNM			0.634		0.765
N0	432 (40.5)	1.57 (1.19-2.07)		125.59 (103.28-156.72)
N1	634 (59.5)	1.68 (1.34-2.24)		132.10 (114.12-149.81)
Multifocality			0.483		0.526
Negative	746 (70)	1.60 (1.23-2.11)		126.06 (105.58-156.75)
Positive	320 (30)	1.53 (1.16-2.04)		126.50 (99.35-154.50)
Hashimoto's thyroiditis			0.005		0.039
Negative	940 (88.2)	1.58 (1.21-2.11)		127.61 (104.89-157.38)
Positive	126 (11.8)	1.52 (1.18-1.89)		119.48 (94.02-147.48)
ETE			0.185		0.805
Negative	654 (61.4)	1.59 (1.20-2.08)		124.31 (103.27-157.95)
Positive	412 (38.6)	1.57 (1.22-2.10)		128.09 (106.15-154.26)
Lateral LNM			0.101		0.316
Negative	1,001 (93.9)	1.57 (1.19-2.07)		125.59 (103.28-156.72)
Positive	65 (6.1)	1.68 (1.34-2.24)		132.10 (114.38-148.46)
LVI			0.155		0.400
Negative	524/715 (73.3)	1.58 (1.21-2.04)		126.96 (103.58-157.59)
Positive	191/715 (26.7)	1.52 (1.13-2.22)		130.18 (104.77-158.92)
BRAF V600E mutation			0.896		0.658
Negative	383/1,003 (38.2)	1.58 (1.17-2.08)		125.96 (101.57-154.28)
Positive	620/1,003 (61.8)	1.57 (1.23-2.10)		125.68 (103.93-156.72)

Statistical significance was tested by the Student t test.

NLR, neutrophil-to-lymphocyte count ratio; PLR, platelet-to-lymphocyte count ratio; IQR, interquartile range; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

Table 2

Comparisons of the Prevalence of Prognostic Factors between Preoperative NLR Quartile Groups

Variable	Group 1	Group 2	Group 3	Group 4	P value
No. in quartile	266	266	266	268
NLR, range	0.25-1.21	1.21-1.57	1.57-2.07	2.08-10.20
Age, yr	51.99±10.64	50.72±11.09	48.96±11.17^a	49.16±11.78^a	0.005
BMI, kg/m²	23.55±3.04	23.37±2.96	24.17±13.33	23.30±3.13	0.482
Tumor size, cm	0.86±0.58	0.92±0.61	0.80±0.53	0.88±0.61	0.131
TSH, mIU/L	1.45 (0.92-2.39)	1.38 (0.84-2.26)	1.33 (0.90-2.13)	1.27 (0.84-2.04)	0.245
T stage 3/4, %	31 (11.7)	25 (9.4)	34 (12.8)	32 (11.9)	0.649
LNM, %	166 (62.4)	157 (59.0)	153 (57.5)	158 (59.0)	0.700
Lateral LNM, %	11 (4.1)	20 (7.5)	15 (5.6)	19 (7.1)	0.350
Multifocality, %	90 (33.8)	81 (30.5)	76 (28.6)	73 (27.2)	0.374
ETE, %	101 (38.0)	110 (41.4)	98 (36.8)	103 (38.4)	0.743
LVI, %	57/187 (30.5)	43/171 (25.1)	32/179 (17.9)	59/178 (33.1)	0.006
BRAF V600E mutation, %	147/252 (58.3)	163/248 (65.7)	153/249 (61.4)	157/254 (61.8)	0.405

Values are expressed as mean±SD, median (interquartile range), or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

NLR, neutrophil-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

^aThe differences were only between quartile group 1 and quartile group 3 and 4 in post hoc analysis.

Table 3

Comparisons of the Prevalence of Prognostic Factors between Preoperative PLR Quartile Groups

Variable	Group 1	Group 2	Group 3	Group 4	P value
No. in quartile	266	266	266	268
PLR, range	13.32-103.85	104.01-125.96	126.0-155.97	156.25-407.81
Age, yr	52.93±10.62	49.56±11.26^a	49.72±11.36^a	48.62±11.25^a	<0.001
BMI, kg/m²	23.87±3.26	23.51±3.23	23.85±13.27	23.16±2.91	0.631
Tumor size, cm	0.87±0.60	0.86±0.60	0.88±0.59	0.84±0.55	0.914
TSH, mIU/L	1.37 (0.90-2.33)	1.32 (0.78-2.10)	1.42 (0.93-2.24)	1.32 (0.87-2.18)	0.212
T stage 3/4, %	33 (12.4)	24 (9.0)	33 (12.4)	32 (11.9)	0.554
LNM, %	159 (59.8)	154 (57.9)	166 (62.4)	155 (57.8)	0.675
Lateral LNM, %	8 (3.0)	18 (6.8)	25 (9.4)	14 (5.2)	0.018
Multifocality, %	90 (33.8)	70 (26.3)	82 (30.8)	78 (29.1)	0.287
ETE, %	96 (36.1)	100 (37.6)	120 (45.1)	96 (35.8)	0.092
LVI, %	46/177 (26.0)	43/168 (25.6)	52/182 (29.1)	49/188 (26.1)	0.865
BRAF V600E mutation, %	155/254 (61.0)	156/249 (62.7)	152/248 (61.3)	157/252 (62.3)	0.978

Values are expressed as mean±SD, median (interquartile range), or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

^aThe differences were significant only between quartile group 1 and quartile group 2, 3, and 4 in post hoc analysis.

Table 4

Relationships between Clinicopathological Characteristics and the Combination of Preoperative NLR and PLR in Papillary Thyroid Cancer Patients

Characteristic	Score 0	Score 1	Score 2	P value
No. in quartile	334	517	215
NLR	1.23 (0.25-1.87)	1.57 (0.57-5.09)	2.50 (1.88-10.20)
PLR	103.95 (13.32-143.82)	125.43 (47.99-294.70)	181.01 (144.07-407.81)
Age, yr	51.58±11.36	50.09±10.95	48.33±11.47^a	0.004
BMI, kg/m²	24.20±11.91	23.34±3.17	23.28±3.07	0.178
Tumor size, cm	0.85±0.57	0.86±0.59	0.88±0.60	0.876
TSH, mIU/L	1.32 (0.79-2.33)	1.43 (0.91-2.24)	1.29 (0.86-2.12)	0.507
T stage 3/4, %	43 (12.9)	52 (10.1)	27 (12.6)	0.383
LNM, %	214 (64.1)	296 (57.3)	124 (57.7)	0.118
Lateral LNM, %	19 (5.7)	34 (6.6)	12 (5.6)	0.817
Multifocality, %	107 (32.0)	153 (29.6)	60 (27.9)	0.563
ETE, %	126 (37.7)	203 (39.3)	83 (38.6)	0.903
LVI, %	65/218 (29.8)	82/343 (23.9)	44/154 (28.6)	0.256
BRAF V600E mutation, %	191/312 (61.2)	305/488 (62.5)	124/203 (61.1)	0.909

Values are expressed as median (interquartile range), mean±SD, or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

NLR, neutrophil-to-lymphocyte count ratio; PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

^aThe differences were significant only between the score 0 and the score 2.

Figure & Data

References

Citations

Citations to this article as recorded by

Preoperative serum inflammation-based scores in medullary thyroid cancer
Ana Abrantes Figueiredo, Susana Esteves, Margarida Maria Moura, Pedro Marques, Joana Simões-Pereira, Valeriano Leite
Endocrinología, Diabetes y Nutrición.2023; 70(1): 48. CrossRef
Preoperative serum inflammation-based scores in medullary thyroid cancer
Ana Abrantes Figueiredo, Susana Esteves, Margarida Maria Moura, Pedro Marques, Joana Simões-Pereira, Valeriano Leite
Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(1): 48. CrossRef
The predictive value of hematologic parameters in the risk of thyroid malignancy in cases with atypia/follicular lesion of undetermined significance
Hayri Bostan, Muhammed Erkam Sencar, Murat Calapkulu, Sema Hepsen, Pinar Akhanli, Hakan Duger, Bekir Ucan, Muhammed Kizilgul, Ilknur Ozturk Unsal, Mustafa Ozbek, Erman Cakal
European Archives of Oto-Rhino-Laryngology.2022; 279(8): 4077. CrossRef
Prognostic Impact of Inflammatory Markers PLR, LMR, PDW, MPV in Medullary Thyroid Carcinoma
Canxiao Li, Han Zhang, Shijie Li, Daqi Zhang, Jingting Li, Gianlorenzo Dionigi, Nan Liang, Hui Sun
Frontiers in Endocrinology.2022;[Epub] CrossRef
The role of neutrophil to lymphocyte and platelet to lymphocyte ratios in diagnosing thyroid nodule
HaiderSalim Mihson, AyadKhani Maikhan, AliRodan Shuwelif
Mustansiriya Medical Journal.2022; 21(2): 155. CrossRef
Comparison of Mean Platelet Volume, Platelet Distribution Width, Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio and Lymphocyte/Monocyte Ratio in Patients with Differentiated Thyroid Cancer According to TSH Levels
Seher ÇETİNKAYA ALTUNTAŞ, Ömercan TOPALOĞLU
Batı Karadeniz Tıp Dergisi.2022; 6(3): 302. CrossRef
Delta Neutrophil Index and Neutrophil-to-Lymphocyte Ratio in the Differentiation of Thyroid Malignancy and Nodular Goiter
Mehmet Buğra Bozan, Fatih Mehmet Yazar, İlhami Taner Kale, Mehmet Fatih Yüzbaşıoğlu, Ömer Faruk Boran, Ayşe Azak Bozan
World Journal of Surgery.2021; 45(2): 507. CrossRef
Factors Affecting Central Node Metastasis and Metastatic Lymph Node Ratio in Papillary Thyroid Cancer
Jungirl Seok, Chang Hwan Ryu, Seog Yun Park, Chang Yoon Lee, Young Ki Lee, Yul Hwangbo, Eun Kyung Lee, You Jin Lee, Tae Sung Kim, Seok‐ki Kim, Yuh‐Seog Jung, Junsun Ryu
Otolaryngology–Head and Neck Surgery.2021; 165(4): 519. CrossRef
Neutrophil to iymphocyte ratio: Does it really differentiate between papillary thyroid carcinomas and multinodular goiter
Hakan BÖLÜKBAŞI, Serhan YILMAZ
Ege Tıp Dergisi.2021; 60(1): 63. CrossRef
Development and Validation of a Nomogram for Preoperative Prediction of Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma and Type 2 Diabetes Mellitus
Chao He, Yiqiao Lu, Binqi Wang, Jie He, Haiguang Liu, Xiaohua Zhang
Cancer Management and Research.2021; Volume 13: 2499. CrossRef
The diagnostic predictive value of neutrophil-to-lymphocyte ratio in thyroid cancer adjusted for tumor size
Taek Yoon Cheong, Sang Duk Hong, Keun-Woo Jung, Yoon Kyoung So, Paula Soares
PLOS ONE.2021; 16(5): e0251446. CrossRef
Usefulness of pre-thyroidectomy neutrophil–lymphocyte, platelet–lymphocyte, and monocyte–lymphocyte ratios for discriminating lymph node and distant metastases in differentiated thyroid cancer
Cínthia Minatel Riguetto, Icléia Siqueira Barreto, Frederico Fernandes Ribeiro Maia, Lígia Vera Montali da Assumpção, Denise Engelbrecht Zantut-Wittmann
Clinics.2021; 76: e3022. CrossRef
Serum Inflammation-based Scores in Endocrine Tumors
Pedro Marques, Friso de Vries, Olaf M Dekkers, Márta Korbonits, Nienke R Biermasz, Alberto M Pereira
The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3796. CrossRef
Diferansiye Tiroid Kanserli Hastalarda Preoperatif Nötrofil / Lenfosit Oranının Boyun Ultrasonografisi ve Patolojik Bulgularla İlişkisi
Mehmet Esat DUYMUŞ
Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi.2021; 54(2): 243. CrossRef
Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer
Sorina Martin, Theodor Mustata, Oana Enache, Oana Ion, Andreea Chifulescu, Anca Sirbu, Carmen Barbu, Adrian Miron, Cosmin Giulea, Florin Andrei, Simona Fica
Diagnostics.2021; 11(11): 1959. CrossRef
The prognostic and diagnostic use of hematological parameters in subacute thyroiditis patients
Murat Calapkulu, Muhammed Erkam Sencar, Davut Sakiz, Hakan Duger, Ilknur Ozturk Unsal, Mustafa Ozbek, Erman Cakal
Endocrine.2020; 68(1): 138. CrossRef
Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis

Wenjie Chen, Tao Wei, Zhihui Li, Rixiang Gong, Jianyong Lei, Jingqiang Zhu, Tao Huang
Cancer Management and Research.2020; Volume 12: 1809. CrossRef
Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma
Haruhiko Yamazaki, Kiminori Sugino, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Hames, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Munetaka Masuda, Koichi Ito
Endocrine.2020; 70(1): 115. CrossRef
Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment
Zhenyu Xie, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Jianjian Sun, Yuchen He, Yu Lun, Jian Zhang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Hipertiroidi Hastalarında Tedavi Öncesi ve Sonrası Trombosit/Lenfosit ve Nötrofil/Lenfosit Oranlarının Değerlendirilmesi
Çiğdem CİNDOĞLU, Mehmet GÜLER, Mehmet Ali EREN, Tevfik SABUNCU
Harran Üniversitesi Tıp Fakültesi Dergisi.2020; 17(1): 104. CrossRef
Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma
Faruk Kutluturk, Serdar S. Gul, Safak Sahin, Turker Tasliyurt
Endocrine, Metabolic & Immune Disorders - Drug Targets.2019; 19(6): 859. CrossRef
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, Luca Modestino, Poupak Fallahi, Silvia Martina Ferrari, Amato de Paulis, Alessandro Antonelli, Maria Rosaria Galdiero
International Journal of Molecular Sciences.2019; 20(16): 3934. CrossRef
Different prognostic values of individual hematologic parameters in papillary thyroid cancer due to age-related changes in immunity
Kwan Ho Lee, Eun Young Seok, Eun Young Kim, Ji Sup Yun, Yong Lai Park, Chan Heun Park
Annals of Surgical Treatment and Research.2019; 96(2): 70. CrossRef
Diagnostic Accuracy of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Detecting Occult Papillary Thyroid Microcarcinomas in Benign Multinodular Goitres
Dimitrios K. Manatakis, Sophia Tseleni-Balafouta, Lazaros Tzelves, Dimitrios Balalis, Adelais Tzortzopoulou, Dimitrios P. Korkolis, George H. Sakorafas, Emmanouil Gontikakis, Georgios Plataniotis
Journal of Thyroid Research.2018; 2018: 1. CrossRef
Assessment of clinical and pathological features of patients who underwent thyroid surgery: A retrospective clinical study
Arif Emre, Sami Akbulut, Mehmet Sertkaya, Muharrem Bitiren, Ilhami Taner Kale, Ertan Bulbuloglu, Cemil Colak
World Journal of Clinical Cases.2018; 6(3): 20. CrossRef
Trends in white blood cell and platelet indices in a comparison of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions
Nikolaos Machairas, Ioannis D. Kostakis, Anastasia Prodromidou, Paraskevas Stamopoulos, Themistoklis Feretis, Zoe Garoufalia, Christos Damaskos, Gerasimos Tsourouflis, Gregory Kouraklis
Endocrine Research.2017; 42(4): 311. CrossRef
Evaluation of Hemocytometer Parameters as Potential Biomarkers in Benign Multinodular Goiter and Papillary Thyroid Carcinoma
Erdal Uysal, Seyit Mehmet Ceylan, Efe Sezgin, Hasan Bakir, Ahmet Orhan Gurer, Basar Aksoy, Mehmet Bastemir
Iranian Red Crescent Medical Journal.2017;[Epub] CrossRef
Clinical Value of Blood Neutrophil to Lymphocyte Ratio in Patients with Papillary Thyroid Carcinoma with Neck Lymph Node Metastasis
Hwa Bin Kim, Hyoung Shin Lee, Sung Won Kim, Seok Won Jeon, Ji Ah Song, Kang Dae Lee
International Journal of Thyroidology.2017; 10(2): 89. CrossRef
Association of Baseline Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics of Papillary Thyroid Carcinoma
Dimitrios K. Manatakis, Sofia Tseleni-Balafouta, Dimitrios Balalis, Vasiliki N. Soulou, Dimitrios P. Korkolis, George H. Sakorafas, Georgios Plataniotis, Emmanouil Gontikakis
International Journal of Endocrinology.2017; 2017: 1. CrossRef
Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma
Ke Jiang, Jianyong Lei, Wenjie Chen, Yanping Gong, Han Luo, Zhihui Li, Rixiang Gong, Jingqiang Zhu
Medicine.2016; 95(40): e5079. CrossRef
Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis
Ji-Feng Liu, Luo Ba, Hong Lv, Dan Lv, Jin-Tao Du, Xiao-Mei Jing, Ning-Jing Yang, Shao-Xin Wang, Chao Li, Xiao-Xia Li
Scientific Reports.2016;[Epub] CrossRef